Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
06 Setembro 2022 - 8:00AM
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company
committed to discovering and delivering the next generation of
precision cancer medicines, today announced that Barbara Weber,
M.D., President and Chief Executive Officer of Tango Therapeutics,
is scheduled to participate in the H.C. Wainwright 24th Annual
Global Investment Conference. The presentation will be available
on-demand starting on Monday, September 12, 2022 at 7:00 AM ET.
A webcast of the event will be available under the “Events &
Presentations” tab on the “Investors” page on the Company's website
on the day of the event. A replay of the webcast will be archived
on the Company's website for approximately 90 days following the
presentation.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to
discovering novel drug targets and delivering the next generation
of precision medicine for the treatment of cancer. Using an
approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Investor Contact:Sam Martin/Andrew VulisArgot
Partnerstango@argotpartners.com
Media Contact:Joshua R. Mansbach Argot Partners
tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024